My watch list
my.chemeurope.com  
Login  

Cisatracurium



Cisatracurium
Systematic (IUPAC) name
5-[3-[(1R,2R)-1-[(3,4-dimethoxyphenyl)methyl]-6,7-
dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-2-yl]
propanoyloxy]pentyl 3-[(1R,2R)-1-[(3,4-dimethoxy
phenyl)methyl]-6,7-dimethoxy-2-methyl-3,4-dihydro-
1H-isoquinolin-2-yl]propanoate
Identifiers
CAS number 96946-42-8
ATC code M03AC11
PubChem 62887
DrugBank APRD00874
Chemical data
Formula C53H72N2O12+2
Mol. mass 929.145 g/mol
Pharmacokinetic data
Bioavailability N/A - IV use only
Protein binding Unknown due to rapid degradation
Metabolism 80% Hoffman elmination/ Hepatic
Half life 20-29 minutes
Excretion 10-15% unchanged
Therapeutic considerations
Pregnancy cat.

B

Legal status
Routes IV only

Cisatracurium (usually as cisatracurium besilate, trade name Nimbex) is a neuromuscular-blocking drug. It is one of the ten isomers of atracurium. Its active metabolites contain less laudanosine which cause hypotension, central nervous system excitement, and seizures than that of atracurium. It is considered an intermediate-acting agent in terms of duration of action.

Additional recommended knowledge

Structure

It is a benzyl-isoquinolinium agent in the quaternary ammonium compound family.

Metabolism

80% is metabolized to laudanosine via Hoffman Elimination (which is dependent on the pH and the temperature of the plasma) and 20% is metabolized hepatically or excreted renally. Since Hoffman elimination is organ-independent, the use of cisatracurium may pose less risk in patients with liver or renal disease than other neuromuscular blockers. 10-15% of the dose is excreted unchanged in the urine.


 
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Cisatracurium". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE